<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392780</url>
  </required_header>
  <id_info>
    <org_study_id>0009-15-RMC</org_study_id>
    <nct_id>NCT02392780</nct_id>
  </id_info>
  <brief_title>Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease</brief_title>
  <official_title>Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>moshe yeshurun</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Graft-versus-host-disease (GVHD) is a major obstacle to successful allogeneic hematopoietic
      cell transplantation (alloHCT). Cannabidiol (CBD), a non-psychotropic ingredient of Cannabis
      sativa possesses potent anti-inflammatory and immunosuppressive properties. In a recent phase
      2 study, CBD has been shown to be safe and reduced significantly the incidence of acute GVHD
      compared to control patients with a hazard ratio of 0.3. Based on these results the
      investigators propose a phase 2 study to explore the efficacy of oral CBD in the treatment of
      severe (grades III/IV) acute GVHD, a pathology with a dismal prognosis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with complete remission of acute GVHD</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with partial remission of acute GVHD</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with chronic GVHD</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients able to discontinue immunosuppression</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Subpopulations of peripheral blood cells and cytokine levels</measure>
    <time_frame>12 months</time_frame>
    <description>T4, T8, Foxp3 T regulatory cells, TNFα, INFγ, IL-1β, IL-6, IL-17, IL-4, IL-5, IL-10 and IL-13</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute-graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Oral cannabidiol at a dose of 150 mg BID up to 90 days.</description>
    <arm_group_label>Cannabidiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>IV methylprednisolone 2 mg/kg/day</description>
    <arm_group_label>Cannabidiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcineurin inhibitor</intervention_name>
    <description>cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)</description>
    <arm_group_label>Cannabidiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years or older

          2. After allogeneic transplantation

          3. Grade III or IV acute GVHD

          4. No psychiatric contra-indication

          5. Informed consent

        Exclusion Criteria:

          1. History of psychosis

          2. Asthma

          3. Known allergy to cannabis constituents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moshe Yeshurun, MD</last_name>
    <phone>972-50-4065543</phone>
    <email>moshey@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liat Shargian, MD</last_name>
    <phone>972-54-2394930</phone>
    <email>LIATSHR@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Davidof Cancer Center, Beilinson hospital, Rabin medical center</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Moshe Yeshurun, MD</last_name>
      <phone>972-50-4065543</phone>
      <email>moshey@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Liat Shargian, MD</last_name>
      <phone>972-54-2394930</phone>
      <email>LIATSHR@clalit.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>moshe yeshurun</investigator_full_name>
    <investigator_title>Head, BMT unit, Rabin Medical Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

